Poison Center Calls For Semaglutide Weight-Loss Drugs More Than Doubled After FDA Approval (opens in new tab)

Covers National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss - Journal of Medical Toxicology

After the FDA's 2021 approval, reported exposures more than doubled, and unintentional therapeutic errors remained the most common reason people contacted poison centers. The post appeared first on <a href="

Read the original article